Abstract:Despite progress in the design of advanced surgical techniques, stenosis recurs in a large percentage of vascular anastomosis. In this study, a novel heparin-poloxamer (HP) hydrogel was designed and its effects for improving the quality and safety of vascular anastomosis were studied. HP copolymer was synthesized and its structure was confirmed by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance spectroscopy ((1)H-NMR). Hydrogels containing HP were prepared and their important characteristics related to the application in vascular anastomosis including gelation temperature, rheological behaviour and micromorphology were measured. Vascular anastomosis were performed on the right common carotid arteries of rabbits, and the in vivo efficiency and safety of HP hydrogel to achieve vascular anastomosis was verified and compared with Poloxamer 407 hydrogel and the conventional hand-sewn method using Doppler ultrasound, CT angiograms, scanning electron microscopy (SEM) and histological technique. Our results showed that HP copolymer displayed special gel-sol-gel phase transition behavior with increasing temperature from 5 to 60 °C. HP hydrogel prepared from 18 wt% HP solution had a porous sponge-like structure, with gelation temperature at approximately 38 °C and maximum elastic modulus at 10,000 Pa. In animal studies, imaging and histological examination of rabbit common jugular artery confirmed that HP hydrogel group had similar equivalent patency, flow and burst strength as Poloxamer 407 group. Moreover, HP hydrogel was superior to poloxamer 407 hydrogel and hand-sewn method for restoring the functions and epithelial structure of the broken vessel junctions after operation. By combining the advantages of heparin and poloxamer 407, HP hydrogel holds high promise for improving vascular anastomosis quality and safety.

Enzymatic Generation of Highly Anticoagulant Bovine Intestinal Heparin.

Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin

Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins.

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Comparison of Low-Molecular-Weight Heparins Prepared from Bovine Lung Heparin and Porcine Intestine Heparin.

Structural Characterization of Pharmaceutical Heparins Prepared from Different Animal Tissues.

Preparation of Low Molecular Weight Heparins from Bovine and Ovine Heparins Using Nitrous Acid Degradation

Chemometric Analysis of Porcine, Bovine and Ovine Heparins.

Optimization of Bioprocess Conditions Improves Production of a CHO Cell-Derived, Bioengineered Heparin.

Control of the Heparosan N-deacetylation Leads to an Improved Bioengineered Heparin

clotting of blood in diseased vessels , and is therefore used to treat deep vein thrombosis and acute coronary syndrome

Correction: Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model.

A Unique Enoxaparin Derived from Bovine Intestinal Heparin: A Single Purification Step of the Starting Material Assures a Bovine Enoxaparin Like the Standard from Porcine Origin

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Immobilized Enzymes to Convert N-sulfo, N-acetyl Heparosan to a Critical Intermediate in the Production of Bioengineered Heparin

Turkey Intestine As a Commercial Source of Heparin? Comparative Structural Studies of Intestinal Avian and Mammalian Glycosaminoglycans

Comparison Of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin

In Vitro Fermentation and Isolation of Heparin-degrading Bacteria from Human Gut Microbiota.

Isolation and Characterization of Raw Heparin from Dromedary Intestine: Evaluation of a New Source of Pharmaceutical Heparin

General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market

High Cell Density Cultivation of Recombinant Escherichia coli Strains Expressing 2- O -Sulfotransferase and C5-Epimerase for the Production of Bioengineered Heparin